Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

ABSTRACT:

Background

A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial.

Methods

Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg/day pioglitazone, or placebo. Investigators were masked to the treatment assignment. Only the statistical centre and the central pharmacy knew the treatment name associated with the randomisation number. The primary outcome was the

SUBMITTER: NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators 

PROVIDER: S-EPMC4574625 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature